All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

ferrous sulfate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4528	7720-78-7

Description:

Molecule	Description
Synonyms: ferrous sulfate ferrous sulfate, dried	Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt Molecular weight: 151.90 Formula: FeO4S CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 80.26 ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	570 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	30.56 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Aug. 13, 1946	FDA	LEDERLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	220.58	10.23	303	49767	1044462	62394490
Acute kidney injury	166.77	10.23	521	49549	262894	63176058
Anaemia	126.80	10.23	512	49558	292918	63146034
Contraindicated product administered	115.58	10.23	17	50053	217631	63221321
Drug intolerance	114.66	10.23	50	50020	308611	63130341
Hand deformity	111.70	10.23	3	50067	159454	63279498
Glossodynia	104.77	10.23	10	50060	178866	63260086
Systemic lupus erythematosus	100.71	10.23	21	50049	208897	63230055
Arthropathy	88.80	10.23	37	50033	234755	63204197
Hepatic enzyme increased	88.41	10.23	25	50045	202303	63236649
Treatment failure	88.08	10.23	24	50046	199019	63239933
Hypervolaemia	85.92	10.23	109	49961	28304	63410648
Joint swelling	73.77	10.23	90	49980	327576	63111376
Pericarditis	72.85	10.23	9	50061	131570	63307382
Therapeutic product effect decreased	72.14	10.23	31	50039	193156	63245796
Rheumatoid arthritis	70.53	10.23	58	50012	253761	63185191
Completed suicide	69.45	10.23	15	50055	145658	63293294
Haemoglobin decreased	69.29	10.23	262	49808	145223	63293729
Discomfort	63.87	10.23	26	50044	167348	63271604
Alopecia	63.78	10.23	105	49965	337431	63101521
Wound	61.27	10.23	26	50044	163237	63275715
Helicobacter infection	60.64	10.23	3	50067	92782	63346170
Pulmonary malformation	55.96	10.23	17	50053	282	63438670
Premature delivery	53.33	10.23	90	49980	30191	63408761
Drug hypersensitivity	52.96	10.23	103	49967	310584	63128368
Infusion related reaction	52.56	10.23	70	50000	245451	63193501
Gastrointestinal haemorrhage	52.52	10.23	162	49908	81014	63357938
Abdominal discomfort	52.46	10.23	109	49961	320776	63118176
Pulmonary hypertension	49.73	10.23	98	49972	37025	63401927
Lung cyst	49.51	10.23	16	50054	328	63438624
Musculoskeletal stiffness	49.05	10.23	44	50026	184574	63254378
Hypersensitivity	49.05	10.23	98	49972	292587	63146365
Melaena	47.94	10.23	86	49984	30279	63408673
Hyperkalaemia	47.71	10.23	121	49949	54082	63384870
Hospitalisation	46.23	10.23	160	49910	84921	63354031
Pulmonary arterial hypertension	45.04	10.23	71	49999	22506	63416446
Respiratory tract malformation	44.97	10.23	13	50057	180	63438772
Hypophosphataemia	43.00	10.23	49	50021	11377	63427575
Acute respiratory failure	41.40	10.23	87	49983	34398	63404554
Folliculitis	40.96	10.23	4	50066	70313	63368639
Death	40.39	10.23	462	49608	373919	63065033
Iron deficiency anaemia	40.11	10.23	63	50007	19906	63419046
Transfusion	39.24	10.23	54	50016	15163	63423789
Arthralgia	38.14	10.23	278	49792	569432	62869520
Cardiac failure acute	37.82	10.23	42	50028	9481	63429471
Pneumonia	37.55	10.23	536	49534	456231	62982721
Impaired healing	37.40	10.23	17	50053	102525	63336427
Muscle injury	37.33	10.23	4	50066	65341	63373611
General physical health deterioration	35.85	10.23	65	50005	201337	63237615
Right ventricular failure	35.60	10.23	55	50015	17133	63421819
Foetal exposure during pregnancy	35.34	10.23	78	49992	31884	63407068
Hypoxia	34.72	10.23	115	49955	59677	63379275
Metabolic acidosis	33.98	10.23	95	49975	44974	63393978
Urinary tract infection	33.81	10.23	338	49732	264346	63174606
Metabolic alkalosis	33.54	10.23	24	50046	3037	63435915
Product use issue	33.46	10.23	78	49992	220442	63218510
Pain	32.61	10.23	401	49669	740227	62698725
Faeces discoloured	32.57	10.23	55	50015	18454	63420498
Psoriatic arthropathy	32.10	10.23	16	50054	91504	63347448
Hypotension	30.99	10.23	340	49730	272264	63166688
Congenital ovarian anomaly	30.29	10.23	6	50064	12	63438940
Transferrin saturation increased	30.18	10.23	7	50063	37	63438915
Cardiac failure congestive	29.76	10.23	148	49922	92285	63346667
Mobility decreased	29.70	10.23	31	50039	121128	63317824
Exposure via breast milk	29.38	10.23	19	50051	2038	63436914
Hypoglycaemia	29.25	10.23	109	49961	59956	63378996
Fall	28.55	10.23	451	49619	391883	63047069
Diarrhoea	27.77	10.23	749	49321	714617	62724335
Pre-eclampsia	27.54	10.23	35	50035	9098	63429854
Congenital skin dimples	27.46	10.23	8	50062	114	63438838
Gastrointestinal tract mucosal pigmentation	27.23	10.23	12	50058	590	63438362
Lactic acidosis	27.20	10.23	79	49991	38208	63400744
Autoimmune haemolytic anaemia	26.88	10.23	25	50045	4576	63434376
Transferrin increased	26.79	10.23	5	50065	6	63438946
Blister	26.76	10.23	38	50032	129776	63309176
Maternal exposure during breast feeding	26.65	10.23	24	50046	4217	63434735
Dyspnoea exertional	26.55	10.23	106	49964	60196	63378756
Sepsis	25.93	10.23	208	49862	152915	63286037
Cellulitis	25.52	10.23	130	49940	81828	63357124
Dyspnoea	25.25	10.23	691	49379	660622	62778330
Swelling	24.91	10.23	122	49948	275256	63163696
Blood loss anaemia	24.81	10.23	33	50037	8968	63429984
Sinus polyp degeneration	23.51	10.23	6	50064	50	63438902
Gingival hypertrophy	22.80	10.23	15	50055	1656	63437296
Irritable bowel syndrome	22.65	10.23	19	50051	82393	63356559
Fluid retention	22.45	10.23	100	49970	59586	63379366
Hypokalaemia	22.14	10.23	149	49921	103655	63335297
Drug abuse	22.13	10.23	15	50055	72503	63366449
Troponin increased	21.83	10.23	33	50037	10088	63428864
Foetal death	21.17	10.23	34	50036	10946	63428006
Hyponatraemia	21.17	10.23	156	49914	111744	63327208
Haemoptysis	21.11	10.23	60	50010	28666	63410286
Chronic obstructive pulmonary disease	20.62	10.23	101	49969	62585	63376367
Hepatic encephalopathy	20.48	10.23	34	50036	11248	63427704
Haematochezia	20.36	10.23	90	49980	53454	63385498
Cardiac failure	20.25	10.23	130	49940	89012	63349940
Chronic kidney disease	20.14	10.23	80	49990	45318	63393634
Diastasis recti abdominis	20.12	10.23	5	50065	37	63438915
Hypoosmolar state	19.99	10.23	7	50063	185	63438767
Therapeutic product effect incomplete	19.96	10.23	43	50027	125013	63313939
Blood iron decreased	19.88	10.23	39	50031	14682	63424270
Anhedonia	19.83	10.23	33	50037	10941	63428011
Infective pulmonary exacerbation of cystic fibrosis	19.37	10.23	29	50041	8788	63430164
C-reactive protein increased	19.24	10.23	28	50042	94679	63344273
Hypomagnesaemia	19.18	10.23	58	50012	28679	63410273
Abdominal pain	18.97	10.23	331	49739	293125	63145827
Oesophageal injury	18.78	10.23	5	50065	50	63438902
Hospice care	18.74	10.23	27	50043	7905	63431047
Mental status changes	18.56	10.23	71	49999	39528	63399424
Glucocorticoids increased	18.43	10.23	6	50064	126	63438826
Thermohypoaesthesia	18.39	10.23	6	50064	127	63438825
Lactation disorder	18.38	10.23	8	50062	382	63438570
Hypothermia	18.36	10.23	36	50034	13545	63425407
Asthenia	18.21	10.23	413	49657	383191	63055761
Sight disability	17.96	10.23	6	50064	137	63438815
Epistaxis	17.73	10.23	108	49962	72617	63366335
Respiratory failure	17.58	10.23	139	49931	101719	63337233
Haematemesis	17.21	10.23	58	50012	30354	63408598
Renal arteriosclerosis	17.12	10.23	5	50065	72	63438880
Fibromyalgia	17.11	10.23	23	50047	80397	63358555
Rectal haemorrhage	16.85	10.23	80	49990	48950	63390002
Hypovolaemia	16.55	10.23	30	50040	10643	63428309
International normalised ratio increased	16.13	10.23	76	49994	46349	63392603
Sopor	16.00	10.23	46	50024	22118	63416834
Atrial fibrillation	15.86	10.23	151	49919	116485	63322467
Foetal malnutrition	15.78	10.23	5	50065	96	63438856
Maternal condition affecting foetus	15.76	10.23	6	50064	202	63438750
Product dose omission issue	15.75	10.23	266	49804	234047	63204905
Renal tubular acidosis	15.69	10.23	12	50058	1680	63437272
Syncope	15.49	10.23	151	49919	117234	63321718
Abdominal distension	15.39	10.23	119	49951	86496	63352456
Blood cholesterol increased	15.28	10.23	32	50038	94000	63344952
Stomatitis	15.27	10.23	57	50013	138668	63300284
Blood creatine phosphokinase MM increased	15.21	10.23	4	50066	38	63438914
Haemorrhoids	15.06	10.23	45	50025	22105	63416847
Genital prolapse	15.02	10.23	4	50066	40	63438912
Threatened labour	15.01	10.23	9	50061	845	63438107
Pulmonary oedema	15.00	10.23	84	49986	54789	63384163
Azotaemia	14.87	10.23	18	50052	4453	63434499
Infected neoplasm	14.60	10.23	6	50064	248	63438704
Congenital cystic lung	14.60	10.23	4	50066	45	63438907
Haemorrhage	14.48	10.23	90	49980	60932	63378020
Internal haemorrhage	14.34	10.23	19	50051	5146	63433806
Clostridium difficile infection	14.31	10.23	54	50016	29868	63409084
Palatal polyp	14.29	10.23	3	50067	9	63438943
Sinus node dysfunction	14.20	10.23	18	50052	4667	63434285
Lower respiratory tract infection	14.15	10.23	55	50015	132252	63306700
Haematocrit decreased	14.11	10.23	65	50005	39275	63399677
Discharge	14.06	10.23	10	50060	1254	63437698
Toxicity to various agents	14.02	10.23	126	49944	247124	63191828
Constipation	13.91	10.23	252	49818	224691	63214261
Haemorrhagic erosive gastritis	13.90	10.23	7	50063	466	63438486
Periodontitis	13.87	10.23	15	50055	3288	63435664
Hypermagnesaemia	13.82	10.23	9	50061	977	63437975
Red blood cell sedimentation rate increased	13.55	10.23	9	50061	43973	63394979
Poor sucking reflex	13.41	10.23	6	50064	306	63438646
Arteriovenous malformation	13.40	10.23	10	50060	1350	63437602
Inflammation	13.37	10.23	28	50042	82245	63356707
COVID-19	13.25	10.23	142	49928	112961	63325991
Uterine leiomyoma	13.19	10.23	25	50045	9173	63429779
Liver injury	13.19	10.23	17	50053	60503	63378449
N-terminal prohormone brain natriuretic peptide increased	13.13	10.23	12	50058	2149	63436803
Blood creatinine increased	13.09	10.23	116	49954	87728	63351224
Unwanted awareness during anaesthesia	12.95	10.23	6	50064	332	63438620
Lethargy	12.92	10.23	82	49988	55925	63383027
Foetal macrosomia	12.66	10.23	4	50066	76	63438876
Full blood count abnormal	12.58	10.23	54	50016	31663	63407289
Bronchial wall thickening	12.54	10.23	10	50060	1489	63437463
Exposure during pregnancy	12.51	10.23	182	49888	155365	63283587
Infection	12.47	10.23	118	49952	229055	63209897
Clostridium difficile colitis	12.33	10.23	40	50030	20529	63418423
Ill-defined disorder	12.32	10.23	29	50041	81726	63357226
Inability to afford medication	12.28	10.23	12	50058	2335	63436617
Rash	12.20	10.23	343	49727	560528	62878424
Ketosis	12.19	10.23	7	50063	606	63438346
Therapy non-responder	12.19	10.23	26	50044	75875	63363077
Application site haematoma	12.10	10.23	3	50067	22	63438930
Dehydration	12.09	10.23	198	49872	173156	63265796
Hyperglycaemia	12.06	10.23	65	50005	41802	63397150
Lower gastrointestinal haemorrhage	12.01	10.23	22	50048	7868	63431084
Gastrointestinal disorder	11.93	10.23	58	50012	131181	63307771
Urine output decreased	11.73	10.23	27	50043	11343	63427609
Therapeutic response decreased	11.72	10.23	19	50051	61506	63377446
Full blood count decreased	11.66	10.23	46	50024	25978	63412974
Urinary retention	11.57	10.23	51	50019	30250	63408702
Hypothyroidism	11.48	10.23	65	50005	42567	63396385
Sleep disorder	11.46	10.23	30	50040	81536	63357416
Musculoskeletal pain	11.45	10.23	36	50034	92241	63346711
Hyponatraemic seizure	11.41	10.23	6	50064	437	63438515
Carbon dioxide increased	11.28	10.23	9	50061	1341	63437611
Umbilical discharge	11.27	10.23	4	50066	110	63438842
Angina unstable	11.07	10.23	20	50050	7075	63431877
Urticaria	10.99	10.23	81	49989	165721	63273231
Bursitis	10.86	10.23	8	50062	37033	63401919
Meningism	10.79	10.23	6	50064	489	63438463
Haemoperitoneum	10.73	10.23	12	50058	2729	63436223
Chest pain	10.69	10.23	234	49836	215725	63223227
Anastomotic stenosis	10.65	10.23	5	50065	285	63438667
Sedation	10.60	10.23	9	50061	38800	63400152
Portal hypertensive gastropathy	10.54	10.23	7	50063	785	63438167
Stillbirth	10.50	10.23	19	50051	6731	63432221
Renal failure	10.40	10.23	140	49930	117512	63321440
Total bile acids increased	10.39	10.23	4	50066	139	63438813
Coma	10.38	10.23	22	50048	64342	63374610
Oxygen consumption increased	10.34	10.23	14	50056	3870	63435082
Vaginal haemorrhage	10.29	10.23	46	50024	27441	63411511
Cellulitis orbital	10.29	10.23	6	50064	535	63438417
Sinus arrest	10.27	10.23	10	50060	1939	63437013

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	79.11	11.87	446	26055	304542	34625888
Drug ineffective	65.77	11.87	157	26344	456594	34473836
Completed suicide	56.01	11.87	5	26496	98163	34832267
Foetal exposure during pregnancy	55.68	11.87	102	26399	37999	34892431
Hyperkalaemia	54.79	11.87	145	26356	69244	34861186
Foetal disorder	46.47	11.87	19	26482	807	34929623
Hospitalisation	46.02	11.87	120	26381	56782	34873648
Anaemia	45.78	11.87	318	26183	233017	34697413
Faeces discoloured	45.05	11.87	56	26445	14822	34915608
Gastrointestinal tract mucosal pigmentation	44.58	11.87	16	26485	474	34929956
Encephalitis toxic	44.47	11.87	14	26487	274	34930156
Periodontitis	38.87	11.87	22	26479	1930	34928500
Lymph node calcification	38.84	11.87	11	26490	147	34930283
Neutropenia neonatal	38.77	11.87	16	26485	696	34929734
Premature baby	38.57	11.87	60	26441	19573	34910857
Haemoglobin decreased	38.27	11.87	187	26314	120585	34809845
Gastrointestinal haemorrhage	32.44	11.87	143	26358	88334	34842096
Asthenia	30.68	11.87	302	26199	244949	34685481
Cardiac dysfunction	30.25	11.87	20	26481	2318	34928112
Hyperlactacidaemia	27.86	11.87	21	26480	2995	34927435
Toxicity to various agents	27.79	11.87	70	26431	200292	34730138
Low birth weight baby	27.61	11.87	32	26469	7873	34922557
Drug abuse	27.41	11.87	21	26480	99075	34831355
Death	27.31	11.87	438	26063	397611	34532819
Ventricular septal defect	24.63	11.87	22	26479	3979	34926451
Gastrointestinal angiodysplasia	24.27	11.87	11	26490	602	34929828
Blood loss anaemia	23.46	11.87	30	26471	8164	34922266
Gingival hypertrophy	22.17	11.87	15	26486	1806	34928624
Fall	21.64	11.87	242	26259	202643	34727787
Full blood count decreased	21.03	11.87	44	26457	18044	34912386
Iron deficiency anaemia	20.89	11.87	32	26469	10297	34920133
Transfusion	20.85	11.87	29	26472	8556	34921874
Foreign body aspiration	20.78	11.87	7	26494	171	34930259
Pancreatic duct stenosis	20.44	11.87	7	26494	180	34930250
Pancreatic mass	20.22	11.87	11	26490	893	34929537
Pancreatic calcification	19.88	11.87	7	26494	196	34930234
Implant site inflammation	19.58	11.87	6	26495	107	34930323
Therapeutic product effect incomplete	19.43	11.87	7	26494	50534	34879896
Hospice care	19.23	11.87	25	26476	6915	34923515
Urinary tract infection	19.09	11.87	119	26382	83962	34846468
Febrile neutropenia	18.81	11.87	48	26453	136801	34793629
Clostridium difficile infection	18.60	11.87	43	26458	18855	34911575
Hypervolaemia	18.48	11.87	44	26457	19665	34910765
Fibrin D dimer increased	17.96	11.87	19	26482	4225	34926205
Diarrhoea	16.79	11.87	400	26101	389512	34540918
Tubulointerstitial nephritis	16.63	11.87	44	26457	20980	34909450
Cortical visual impairment	15.87	11.87	4	26497	33	34930397
Exposure during pregnancy	15.75	11.87	26	26475	8908	34921522
Hypotension	15.16	11.87	244	26257	221405	34709025
Benign soft tissue neoplasm	15.04	11.87	5	26496	117	34930313
Dysaesthesia	14.84	11.87	13	26488	2292	34928138
Cardiac ventricular disorder	14.67	11.87	6	26495	255	34930175
Dyspnoea	14.57	11.87	381	26120	376401	34554029
Decreased appetite	14.46	11.87	191	26310	166201	34764229
Treatment failure	14.09	11.87	9	26492	46688	34883742
Feeding intolerance	13.78	11.87	5	26496	153	34930277
Pancreatic injury	13.75	11.87	5	26496	154	34930276
Intracardiac mass	13.42	11.87	5	26496	165	34930265
Pericardial effusion	13.23	11.87	45	26456	24617	34905813
Bone marrow failure	13.18	11.87	3	26498	29250	34901180
Asocial behaviour	13.12	11.87	4	26497	70	34930360
Acute respiratory failure	12.88	11.87	52	26449	30876	34899554
Enterocolitis bacterial	12.82	11.87	6	26495	354	34930076
Crystal urine	12.72	11.87	4	26497	78	34930352
Fistula discharge	12.62	11.87	8	26493	863	34929567
Nasal flaring	12.59	11.87	3	26498	19	34930411
Suicide attempt	12.56	11.87	7	26494	39109	34891321
Flight of ideas	12.55	11.87	6	26495	371	34930059
Failure to thrive	12.52	11.87	23	26478	8578	34921852
Ludwig angina	12.49	11.87	5	26496	201	34930229
Upper gastrointestinal haemorrhage	12.35	11.87	45	26456	25473	34904957
Renal cyst ruptured	12.33	11.87	3	26498	21	34930409
Bronchial obstruction	12.22	11.87	10	26491	1606	34928824

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	231.61	10.32	930	63517	518474	79161467
Drug ineffective	194.72	10.32	362	64085	1080551	78599390
Anaemia	145.37	10.32	727	63720	444288	79235653
Completed suicide	132.96	10.32	20	64427	245747	79434194
Hypervolaemia	100.67	10.32	147	64300	42543	79637398
Hyperkalaemia	100.47	10.32	259	64188	114139	79565802
Drug intolerance	92.56	10.32	49	64398	264070	79415871
Haemoglobin decreased	92.46	10.32	390	64057	221729	79458212
Gastrointestinal haemorrhage	86.11	10.32	289	64158	147430	79532511
Contraindicated product administered	74.20	10.32	18	64429	157520	79522421
Faeces discoloured	71.15	10.32	102	64345	29025	79650916
Gastrointestinal tract mucosal pigmentation	70.75	10.32	28	64419	1022	79678919
Hepatic enzyme increased	68.31	10.32	31	64416	182579	79497362
Hospitalisation	65.55	10.32	196	64251	94040	79585901
Treatment failure	65.26	10.32	28	64419	170458	79509483
Joint swelling	64.68	10.32	83	64364	288563	79391378
Arthropathy	60.36	10.32	34	64413	177077	79502864
Death	57.22	10.32	704	63743	565810	79114131
Transfusion	57.01	10.32	78	64369	21252	79658689
Periodontitis	52.51	10.32	37	64410	4459	79675482
Therapeutic product effect decreased	52.28	10.32	34	64413	163829	79516112
Drug abuse	51.57	10.32	34	64413	162657	79517284
Systemic lupus erythematosus	51.20	10.32	17	64430	121132	79558809
Drug hypersensitivity	50.92	10.32	103	64344	298813	79381128
Toxicity to various agents	50.66	10.32	173	64274	421367	79258574
Glossodynia	48.27	10.32	12	64435	103325	79576616
Pulmonary arterial hypertension	48.04	10.32	84	64363	28282	79651659
Iron deficiency anaemia	47.40	10.32	79	64368	25593	79654348
Gingival hypertrophy	46.63	10.32	30	64417	3112	79676829
Pulmonary hypertension	46.53	10.32	113	64334	47967	79631974
Pulmonary malformation	46.51	10.32	14	64433	219	79679722
Musculoskeletal stiffness	46.13	10.32	44	64403	174964	79504977
Melaena	44.58	10.32	129	64318	60761	79619180
Rheumatoid arthritis	43.59	10.32	63	64384	208407	79471534
Pericarditis	43.39	10.32	15	64432	104221	79575720
Infusion related reaction	43.02	10.32	75	64372	230162	79449779
Dyspnoea	43.00	10.32	949	63498	856076	78823865
Fall	42.48	10.32	590	63857	487039	79192902
Duodenal ulcer perforation	41.89	10.32	3	64444	66208	79613733
Lung cyst	41.68	10.32	14	64433	317	79679624
Acute respiratory failure	40.60	10.32	123	64324	59418	79620523
Blood loss anaemia	40.41	10.32	56	64391	15442	79664499
Discomfort	40.15	10.32	26	64421	125591	79554350
Encephalitis toxic	39.31	10.32	13	64434	280	79679661
Hypotension	39.25	10.32	535	63912	439782	79240159
Helicobacter infection	39.24	10.32	5	64442	69699	79610242
Cardiac failure acute	38.69	10.32	61	64386	18868	79661073
Arthralgia	38.17	10.32	288	64159	571515	79108426
Alopecia	37.47	10.32	82	64365	231273	79448668
Hypoxia	36.65	10.32	173	64274	103070	79576871
Haematemesis	35.66	10.32	108	64339	52156	79627785
Urinary tract infection	34.83	10.32	357	64090	274155	79405786
Cardiac failure congestive	33.91	10.32	214	64233	142188	79537753
Premature delivery	32.82	10.32	64	64383	23403	79656538
Impaired healing	32.58	10.32	15	64432	87640	79592301
Metabolic acidosis	32.05	10.32	142	64305	82387	79597554
Respiratory tract malformation	31.65	10.32	9	64438	114	79679827
Folliculitis	31.11	10.32	4	64443	55376	79624565
Therapeutic product effect incomplete	30.40	10.32	42	64405	141603	79538338
Right ventricular failure	29.19	10.32	61	64386	23436	79656505
Haematochezia	29.04	10.32	144	64303	87501	79592440
Hyponatraemia	28.94	10.32	244	64203	177604	79502337
Hypoglycaemia	28.90	10.32	160	64287	101434	79578507
Foetal death	28.76	10.32	34	64413	8010	79671931
Psoriatic arthropathy	27.99	10.32	14	64433	77985	79601956
Hospice care	27.96	10.32	38	64409	10286	79669655
Lymph node calcification	27.73	10.32	11	64436	404	79679537
Diarrhoea	27.48	10.32	917	63530	879572	78800369
Wound	27.48	10.32	32	64415	116147	79563794
Lactic acidosis	27.27	10.32	121	64326	70238	79609703
Pre-eclampsia	27.25	10.32	31	64416	7010	79672931
Pneumonia	27.22	10.32	712	63735	659534	79020407
Asthenia	26.96	10.32	571	63876	511118	79168823
Exposure via breast milk	26.79	10.32	14	64433	982	79678959
Chronic kidney disease	26.58	10.32	115	64332	66039	79613902
Transferrin saturation increased	26.24	10.32	8	64439	131	79679810
Clostridium difficile infection	26.17	10.32	85	64362	42600	79637341
Dyspnoea exertional	25.35	10.32	138	64309	86935	79593006
Mental status changes	25.08	10.32	114	64333	66845	79613096
Metabolic alkalosis	24.98	10.32	24	64423	4465	79675476
Hypersensitivity	24.90	10.32	118	64329	262121	79417820
Fluid retention	24.06	10.32	116	64331	69693	79610248
Maternal exposure during breast feeding	23.78	10.32	19	64428	2766	79677175
Cardiac failure	23.39	10.32	209	64238	154633	79525308
Sinus polyp degeneration	23.37	10.32	6	64441	50	79679891
Chronic obstructive pulmonary disease	23.28	10.32	133	64314	85286	79594655
Sopor	23.26	10.32	69	64378	32941	79647000
Hypokalaemia	23.10	10.32	197	64250	143843	79536098
Pain	22.52	10.32	417	64030	703385	78976556
Fibromyalgia	22.42	10.32	12	64435	64328	79615613
Hypovolaemia	22.06	10.32	46	64401	17645	79662296
Bone marrow failure	21.89	10.32	7	64440	51100	79628841
Mobility decreased	21.73	10.32	41	64406	122134	79557807
Transferrin increased	21.67	10.32	5	64442	25	79679916
General physical health deterioration	21.62	10.32	132	64315	275106	79404835
Pancreatic duct stenosis	21.57	10.32	8	64439	244	79679697
Hypothermia	21.51	10.32	53	64394	22693	79657248
Lower gastrointestinal haemorrhage	21.37	10.32	43	64404	16082	79663859
Blood cholesterol increased	20.96	10.32	22	64425	83698	79596243
Haemoptysis	20.72	10.32	95	64352	55904	79624037
Upper gastrointestinal haemorrhage	20.67	10.32	77	64370	41303	79638638
Drug dependence	20.52	10.32	4	64443	40765	79639176
Product dose omission issue	20.49	10.32	297	64150	247240	79432701
Gastrointestinal angiodysplasia	20.44	10.32	12	64435	1057	79678884
Inflammation	19.91	10.32	28	64419	93725	79586216
Cytomegalovirus infection	19.82	10.32	5	64442	42639	79637302
Inability to afford medication	19.69	10.32	17	64430	2756	79677185
Fibroma	19.66	10.32	11	64436	884	79679057
Oesophageal injury	19.47	10.32	6	64441	102	79679839
Abdominal pain	19.30	10.32	431	64016	389138	79290803
Tubulointerstitial nephritis	18.98	10.32	71	64376	38164	79641777
Drug eruption	18.85	10.32	6	64441	43929	79636012
Pulmonary oedema	18.79	10.32	129	64318	88125	79591816
Syncope	18.46	10.32	224	64223	179225	79500716
Irritable bowel syndrome	18.41	10.32	14	64433	62227	79617714
Sepsis	18.40	10.32	313	64134	269115	79410826
Rectal haemorrhage	18.36	10.32	115	64332	76185	79603756
Abdominal discomfort	18.28	10.32	123	64324	250604	79429337
Glucocorticoids increased	18.20	10.32	6	64441	128	79679813
Poor sucking reflex	18.15	10.32	6	64441	129	79679812
International normalised ratio increased	18.14	10.32	124	64323	84597	79595344
Lactation disorder	18.13	10.32	7	64440	239	79679702
Pancreatic calcification	17.83	10.32	7	64440	250	79679691
Urticaria	17.77	10.32	83	64364	185118	79494823
Respiratory failure	17.39	10.32	223	64224	180688	79499253
Flight of ideas	17.34	10.32	10	64437	852	79679089
Abdominal distension	17.30	10.32	160	64287	119490	79560451
Implant site inflammation	17.30	10.32	7	64440	271	79679670
Discharge	17.06	10.32	12	64435	1442	79678499
Cellulitis	16.88	10.32	148	64299	108912	79571029
Maternal condition affecting foetus	16.87	10.32	6	64441	162	79679779
Infective pulmonary exacerbation of cystic fibrosis	16.71	10.32	34	64413	12817	79667124
Cortical visual impairment	16.45	10.32	4	64443	26	79679915
Small intestinal obstruction	16.44	10.32	54	64393	27218	79652723
Infection	16.43	10.32	121	64326	241591	79438350
Myelosuppression	16.42	10.32	6	64441	40290	79639651
Foreign body aspiration	16.10	10.32	7	64440	325	79679616
Clostridium difficile colitis	16.07	10.32	60	64387	32223	79647718
Drug resistance	16.03	10.32	7	64440	42206	79637735
Haemorrhage	15.88	10.32	127	64320	90991	79588950
Hypoosmolar state	15.80	10.32	7	64440	340	79679601
Mucosal inflammation	15.63	10.32	23	64424	75557	79604384
Hepatic encephalopathy	15.61	10.32	49	64398	24117	79655824
Epistaxis	15.56	10.32	148	64299	111367	79568574
Hypomagnesaemia	15.48	10.32	77	64370	46834	79633107
Nasopharyngitis	15.44	10.32	131	64316	253750	79426191
Secretion discharge	15.28	10.32	36	64411	14986	79664955
Haemorrhoids	15.22	10.32	55	64392	29073	79650868
Hip fracture	15.17	10.32	57	64390	30704	79649237
Blood creatine phosphokinase MM increased	14.84	10.32	4	64443	41	79679900
Thermohypoaesthesia	14.73	10.32	5	64442	117	79679824
Blood iron decreased	14.64	10.32	36	64411	15398	79664543
Sinus node dysfunction	14.62	10.32	24	64423	7677	79672264
Stillbirth	14.61	10.32	17	64430	3938	79676003
Acidosis	14.59	10.32	42	64405	19720	79660221
Drug ineffective for unapproved indication	14.55	10.32	12	64435	51226	79628715
Benign soft tissue neoplasm	14.34	10.32	5	64442	127	79679814
Troponin increased	14.29	10.32	41	64406	19214	79660727
Pancreatic mass	14.27	10.32	11	64436	1520	79678421
Hyperlactacidaemia	14.26	10.32	20	64427	5575	79674366
Inflammatory bowel disease	14.11	10.32	20	64427	5631	79674310
Red blood cell sedimentation rate increased	14.02	10.32	10	64437	45932	79634009
Lethargy	14.00	10.32	113	64334	81179	79598762
Hypermagnesaemia	13.98	10.32	10	64437	1234	79678707
Sight disability	13.95	10.32	5	64442	138	79679803
Atrial fibrillation	13.91	10.32	231	64216	197655	79482286
Dehydration	13.70	10.32	279	64168	247908	79432033
Iron deficiency	13.63	10.32	28	64419	10626	79669315
Haemorrhagic erosive gastritis	13.36	10.32	8	64439	731	79679210
Uterine haemorrhage	13.36	10.32	14	64433	2889	79677052
Azotaemia	13.36	10.32	24	64423	8252	79671689
Therapeutic response decreased	13.19	10.32	21	64426	66832	79613109
Bronchopulmonary disease	13.17	10.32	3	64444	14	79679927
Autoimmune haemolytic anaemia	13.14	10.32	24	64423	8356	79671585
Therapy non-responder	13.12	10.32	35	64412	92270	79587671
Exposure during pregnancy	13.03	10.32	132	64315	101000	79578941
Haemosiderosis	13.02	10.32	7	64440	520	79679421
Unwanted awareness during anaesthesia	13.02	10.32	6	64441	320	79679621
Vaginal haemorrhage	12.97	10.32	43	64404	21774	79658167
Renal cyst ruptured	12.93	10.32	4	64443	69	79679872
Arteriovenous malformation	12.92	10.32	11	64436	1750	79678191
Renal arteriosclerosis	12.91	10.32	6	64441	326	79679615
Colitis ulcerative	12.90	10.32	59	64388	34683	79645258
C-reactive protein increased	12.87	10.32	57	64390	128970	79550971
Intentional product misuse	12.85	10.32	37	64410	95128	79584813
Stomatitis	12.80	10.32	68	64379	146689	79533252
Hyperhidrosis	12.77	10.32	71	64376	151421	79528520
Sleep disorder	12.55	10.32	32	64415	85645	79594296
Oedema peripheral	12.44	10.32	279	64168	252009	79427932
Cardiac dysfunction	12.43	10.32	16	64431	4108	79675833
Musculoskeletal pain	12.27	10.32	42	64405	102312	79577629
Asocial behaviour	12.19	10.32	4	64443	84	79679857
Infected neoplasm	12.19	10.32	6	64441	371	79679570
Uterine leiomyoma	12.12	10.32	20	64427	6423	79673518
Urinary tract infection bacterial	12.09	10.32	20	64427	6436	79673505
Haemoglobin abnormal	12.09	10.32	21	64426	7033	79672908
Regurgitation	12.04	10.32	13	64434	2774	79677167
Bursitis	12.03	10.32	7	64440	35837	79644104
Large intestinal obstruction	11.89	10.32	14	64433	3285	79676656
Premature labour	11.88	10.32	23	64424	8367	79671574
Off label use	11.86	10.32	606	63841	906609	78773332
Colon cancer	11.84	10.32	32	64415	14491	79665450
Blister	11.78	10.32	53	64394	119423	79560518
Bradycardia	11.74	10.32	164	64283	135393	79544548
Failure to thrive	11.63	10.32	28	64419	11816	79668125
Intracardiac mass	11.63	10.32	5	64442	226	79679715
Pancreatic injury	11.61	10.32	5	64442	227	79679714
Therapy interrupted	11.47	10.32	53	64394	31288	79648653
Gastric antral vascular ectasia	11.46	10.32	8	64439	950	79678991
Respiratory depression	11.45	10.32	4	64443	27626	79652315
Fibrin D dimer increased	11.38	10.32	23	64424	8631	79671310
Hiatus hernia	11.33	10.32	43	64404	23269	79656672
Febrile neutropenia	11.18	10.32	126	64321	230873	79449068
Hepatic cytolysis	11.14	10.32	4	64443	27147	79652794
Meningism	11.05	10.32	7	64440	707	79679234
Accidental overdose	11.03	10.32	62	64385	39519	79640422
Rash	11.01	10.32	370	64077	577988	79101953
Chronic hepatic failure	11.01	10.32	8	64439	1011	79678930
Blood creatinine increased	10.89	10.32	181	64266	154876	79525065
Ludwig angina	10.76	10.32	5	64442	272	79679669
Meconium in amniotic fluid	10.75	10.32	4	64443	123	79679818
Crystal urine	10.63	10.32	4	64443	127	79679814
Sedation	10.53	10.32	16	64431	51879	79628062
Haematuria	10.43	10.32	93	64354	68743	79611198
Cognitive disorder	10.33	10.32	26	64421	69900	79610041
Product use issue	10.33	10.32	114	64333	209708	79470233
Cellulitis orbital	10.33	10.32	7	64440	792	79679149

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B03AA07	BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS IRON PREPARATIONS Iron bivalent, oral preparations
ATC	B03AD03	BLOOD AND BLOOD FORMING ORGANS ANTIANEMIC PREPARATIONS IRON PREPARATIONS Iron in combination with folic acid
CHEBI has role	CHEBI:63247	reducer

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Anemia of prematurity	indication	47100003	DOID:11243
Megaloblastic anemia due to folate deficiency	indication	85649008	DOID:14026
Vitamin deficiency	indication	85670002
Iron deficiency anemia	indication	87522002
Mineral deficiency	indication	111379007
Mineral Deficiency Prevention	indication
Vitamin Deficiency Prevention	indication
Peptic ulcer	contraindication	13200003	DOID:750
Operation on stomach	contraindication	16453004
Primary hyperoxaluria	contraindication	17901006	DOID:2977
Gastroenteritis	contraindication	25374005	DOID:2326
Hemosiderosis	contraindication	39011001	DOID:12119
Hemolytic anemia	contraindication	61261009	DOID:583
Ulcerative colitis	contraindication	64766004	DOID:8577
Anemia due to enzyme deficiency	contraindication	111577008
Hb SS disease	contraindication	127040003	DOID:10923
Esophageal dysmotility	contraindication	266434009	DOID:9192
Diverticular disease	contraindication	397881000
Hemochromatosis	contraindication	399187006	DOID:2352
Repeated Blood Transfusions	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04172	KEGG_DRUG
4017707	VUID
N0000146077	NUI
4017662	VANDF
4017664	VANDF
4017707	VANDF
CHEBI:75832	CHEBI
CHEMBL1200830	ChEMBL_ID
C020748	MESH_SUPPLEMENTAL_RECORD_UI
39R4TAN1VT	UNII
24947	RXNORM
4725	MMSL
4920	MMSL
6168	MMSL
63844	MMSL
d03824	MMSL
000840	NDDF
007813	NDDF
387402000	SNOMEDCT_US
71724000	SNOMEDCT_US
C0060282	UMLSCUI
24393	PUBCHEM_CID
7782-63-0	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Quflora FE Pediatric Drops	HUMAN PRESCRIPTION DRUG LABEL	14	15370-102	LIQUID	9.50 mg	ORAL	UNAPPROVED DRUG OTHER	11 sections
FERROUS SULFATE	HUMAN OTC DRUG LABEL	1	50436-5890	TABLET	325 mg	ORAL	Unapproved drug other	10 sections
FERROUS SULFATE	HUMAN OTC DRUG LABEL	1	53807-177	ELIXIR	220 mg	ORAL	UNAPPROVED DRUG OTHER	15 sections
FERROUS SULFATE	HUMAN OTC DRUG LABEL	1	53808-0918	TABLET	325 mg	ORAL	UNAPPROVED DRUG OTHER	10 sections
Ferrous Sulfate	HUMAN OTC DRUG LABEL	1	54738-963	TABLET	325 mg	ORAL	unapproved drug other	11 sections
Ferrous Sulfate	HUMAN OTC DRUG LABEL	1	54738-963	TABLET	325 mg	ORAL	unapproved drug other	11 sections
FERROUS SULFATE	HUMAN OTC DRUG LABEL	2	58607-113	TABLET	65 mg	ORAL	unapproved drug other	9 sections
Multi-Vitamin Drops with Fluoride and Iron	HUMAN PRESCRIPTION DRUG LABEL	10	58657-327	LIQUID	10 mg	ORAL	unapproved drug other	10 sections
Multi-Vitamin Drops with Fluoride and Iron	HUMAN PRESCRIPTION DRUG LABEL	10	58657-327	LIQUID	10 mg	ORAL	unapproved drug other	10 sections
Ferrous Sulfate	HUMAN OTC DRUG LABEL	1	67296-1555	TABLET, FILM COATED	325 mg	ORAL	unapproved drug other	10 sections
Ferrous Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	69517-133	TABLET	65 mg	ORAL	unapproved drug other	6 sections
Ferrous Sulfate	Human OTC Drug Label	1	76413-308	TABLET, FILM COATED	325 mg	ORAL	UNAPPROVED DRUG OTHER	10 sections
Ferrous Sulfate	Human OTC Drug Label	1	76413-356	TABLET, FILM COATED	325 mg	ORAL	UNAPPROVED DRUG OTHER	11 sections